FDA PCAC Docket FDA-2025-N-6895: How to Submit a Public Comment on Peptide Compounding Before July 9

What's Actually Happening in This Docket

On April 16, 2026, the Federal Register published the formal notice for the Pharmacy Compounding Advisory Committee meeting scheduled for July 23–24, 2026. The notice (Volume 91, Issue 73) opened public docket FDA-2025-N-6895 on regulations.gov for written submissions. The docket will accept comments through July 22, 2026, with a priority cutoff of July 9 for inclusion in the committee's pre-read packet.

The PCAC is a federal advisory committee that helps the FDA decide which active pharmaceutical ingredients should appear on the 503A bulks list — the list of substances that compounding pharmacies are explicitly allowed to use when filling individualized patient prescriptions. The list exists because compounding pharmacies need a clear, FDA-vetted catalog of substances they can legally formulate. Substances that are not on the list, and not otherwise FDA-approved as finished drug products, cannot be compounded for individual patients.

This particular meeting is unusual because it concentrates the agenda on seven peptides that have been used widely in the research and biohacking community for years but have never been formally evaluated for inclusion on the 503A list. The committee's recommendation will not directly create or eliminate a market — research-chemical peptide sales already exist in a separate regulatory channel — but it will determine whether US patients can legally obtain these peptides through a physician's prescription.

The Seven Peptides Up for Review

Each peptide on the agenda is being nominated for a specific indication, listed in the Federal Register notice. The committee evaluates each peptide's safety and efficacy package against its nominated use, not against the off-label or research-community uses that may be more familiar to readers.

The mismatch between nominated indication and community use matters for two reasons. First, the committee's safety/efficacy evaluation will weigh studies and clinical reports against the specific indication on file — a TB-500 study in cardiac wound healing carries more weight for a wound-healing nomination than a BPC-157 study in tendon repair. Second, even if a peptide is added to the 503A list, the prescription pathway in clinical practice will tie to its nominated indication. A physician who wants to prescribe BPC-157 for a partial Achilles tear, after inclusion, would still be doing so off-label — legal, but at the physician's discretion.

What's NOT on the Agenda

Several peptides that the research community might expect are absent from this docket. CJC-1295, ipamorelin, tesamorelin, and the GLP-1 family are not under PCAC review at this meeting because their regulatory status is being addressed through other channels (some are FDA-approved finished drugs, some are subject to separate compounding pathways). PT-141, melanotan II, hexarelin, and most growth-hormone secretagogues are also not in this docket. Future PCAC meetings may address them; this one will not.

The Two Deadlines That Actually Matter

Two dates show up in the Federal Register notice. They are not equivalent.

The functional difference between the two is large. PCAC committee members typically receive their pre-read packet about two weeks before the meeting — the July 9 cutoff aligns with that. Public testimony at the meeting is also invited, but it follows a strict time limit per speaker (typically three to five minutes) and is not a substitute for written comments.

Practically: if your goal is to influence how committee members vote, target the July 9 deadline. If your goal is to enter your position into the public record so that future regulatory actions can reference it, the July 22 cutoff is sufficient. The two goals can be combined by submitting a primary comment before July 9 and supplementing with additional evidence later.

How to File a Public Comment, Step by Step

The process is intentionally simple. Every step happens on regulations.gov.

Step 1: Open the Docket

Navigate to regulations.gov and search for FDA-2025-N-6895 in the search bar at the top of the page. The docket page will appear in the results. Open it. The page will list the Federal Register notice, any supporting documents the FDA has filed, and a "Submit a formal comment" button (sometimes worded as "Comment now").

Step 2: Click "Submit a formal comment"

You will be taken to a comment form. The form includes fields for your name (optional), organization (optional), email (optional, used only for confirmation), country, state, and city. None of these are mandatory. The largest field is the comment body itself, plus an option to upload supporting documents (PDFs of studies you cite, data tables, your CV if relevant).

Step 3: Write the Comment in a Word Processor First

Do not write the comment directly in the regulations.gov text box. Sessions can time out, browsers can crash, and the box has minimal formatting tools. Compose your comment in Word, Google Docs, or any text editor, polish it, and then paste it into the regulations.gov box. Save your draft locally before submitting.

Step 4: Submit and Save the Confirmation

After submitting, regulations.gov will email a confirmation with a tracking ID. Save that ID. Comments typically appear in the public docket within one to three business days, with a short delay while staff review the submission for personally identifying information.

Step 5 (Optional): Register to Speak at the Open Session

If you want to deliver oral testimony at the July 23–24 meeting, the Federal Register notice will list a separate registration process (usually an email address with a deadline approximately three weeks before the meeting). Spots are limited and granted in registration order.

What to Actually Say in Your Comment

Effective comments share a small number of structural features. None of them require professional polish — the FDA explicitly invites comments from any interested party — but the structure consistently outperforms generic statements of support or opposition.

The Five-Part Comment Skeleton

1. Identify yourself in one sentence. "I am a sports medicine physician in Boulder, Colorado, who has prescribed peptide therapies in research settings for eleven years." Or: "I am a patient with chronic ulcerative colitis who has researched BPC-157 as a complementary therapy after standard biologics failed." The committee weighs comments more heavily when context is clear.

2. State your position in one sentence. "I support adding BPC-157 to the 503A bulks list with the indication of ulcerative colitis as nominated." Make it unambiguous. Hedged positions are harder to count.

3. Cite at least two peer-reviewed studies with PMIDs. Each citation should include the lead author, year, journal, and PubMed ID. Include the relevance in one sentence. "Sikiric et al. (2010, Current Pharmaceutical Design, PMID 20218977) demonstrated BPC-157's gut-protective effects in multiple animal models of inflammatory bowel disease — directly relevant to the nominated indication."

4. Describe a specific use case. Either personal experience (a patient case, your own use as a researcher) or research-protocol use ("In our IRB-approved investigator-led study at the University of X..."). Specificity is the single biggest predictor of comment weight.

5. Close with a clear ask. "I urge the committee to recommend adding BPC-157 to the 503A bulks list with the nominated indication of ulcerative colitis. The peer-reviewed evidence supports a favorable safety profile, and inclusion would expand legitimate, prescription-pathway access for patients with refractory disease."

What Effective Comments Avoid

• Form-letter language. Copy-paste comments from advocacy groups are counted but weighted minimally. The committee can identify identical paragraphs and treats them as a single bloc.
• Generic enthusiasm. "I love peptides" or "BPC-157 changed my life" without specifics adds little signal.
• Hostile or political tone. Comments that attack the FDA, individual committee members, or the regulatory process are typically read but rarely persuasive. The committee is composed of pharmacy and clinical experts who respond to evidence and reasoning, not pressure.
• Unverified claims. Statements like "BPC-157 is the safest peptide ever discovered" without supporting data are easily dismissed. Specific, citable claims with appropriate uncertainty ("In rodent models, BPC-157 shows a favorable safety profile across the dose ranges tested...") survive scrutiny.
• Off-topic content. Stay on the nominated peptides and their indications. Comments that pivot to unrelated peptides or general drug-policy positions get filtered.

Evidence to Cite, Per Peptide

The strongest comments cite peer-reviewed literature. Below is a starting point for each peptide on the agenda. These are reference points, not an exhaustive list — adapt them to your specific argument.

BPC-157 (Nominated for Ulcerative Colitis)

The Sikiric research group has published the bulk of the BPC-157 literature, much of it focused on gastrointestinal protection. PubMed searches for "BPC-157 colitis" return dozens of rodent-model studies showing reduced colonic damage, faster mucosal healing, and modulation of inflammatory cytokines. For the nominated indication, the strongest citations are the gut-specific studies; off-label tendon-repair studies are weaker for this docket because they don't address the nominated use.

TB-500 (Nominated for Wound Healing)

Thymosin beta-4 (the parent molecule of TB-500's active fragment) has a substantial peer-reviewed literature on wound healing in animal models, with smaller human trials in dermal wounds, corneal healing, and post-cardiac-surgery recovery. The Goldstein and Hannappel research groups are foundational citation sources. For this nomination, focus on wound-healing-specific studies rather than the broader athletic-recovery literature.

KPV (Nominated for IBD)

KPV is a tripeptide derived from alpha-MSH with anti-inflammatory activity in the gut and skin. The Charoenphandhu and Eberle groups have published mucosal-inflammation studies relevant to the nominated IBD indication. Citations should focus on the colitis and Crohn's disease literature rather than the topical-dermatology studies.

MOTs-C (Nominated for Type 2 Diabetes)

MOTs-C is a mitochondrially-derived peptide with documented effects on insulin sensitivity, glucose homeostasis, and exercise capacity. The Cohen lab at USC has been the primary academic source. For this docket, cite the metabolic and insulin-sensitivity studies; the exercise-capacity literature is supportive but secondary to the nominated diabetes indication.

Semax (Nominated for Cognitive Decline)

Semax has the longest clinical-use history of any peptide on the agenda — it has been used clinically in Russia for stroke recovery and cognitive impairment for decades. The translated Russian clinical literature plus more recent neuroprotection mechanistic studies (BDNF upregulation, monoamine modulation) form the strongest citation base for the nominated indication.

Epitalon (Nominated for Pineal-Gland Aging)

The Khavinson research group in St. Petersburg has published the bulk of Epitalon's clinical and preclinical literature, including human trials in elderly populations showing markers of biological-age improvement. Citations should focus on the pineal-gland and biological-aging studies rather than the broader anti-aging community claims.

DSIP / Emideltide (Nominated for Sleep Disorders)

Delta sleep-inducing peptide has a moderate clinical literature on sleep-architecture effects, with human trials in chronic pain populations and stress-related insomnia. The Schoenenberger and Monnier original isolation papers plus modern sleep-architecture studies provide a citation base aligned with the nominated indication.

What Happens at the July 23–24 Meeting

The PCAC meeting is a structured two-day open session. Day one typically covers half the agenda; day two covers the rest plus committee discussion and votes. The general flow per peptide is:

1. FDA staff presentation summarizing the substance, the nominated indication, and the FDA's evaluation of safety and efficacy data.
2. Open public hearing. Pre-registered speakers deliver brief oral testimony — typically three to five minutes per speaker, capped at a fixed total time.
3. Committee discussion. Members ask questions of FDA staff and discuss the substance among themselves.
4. Committee vote. Members vote on a structured set of questions: should the substance be added to the 503A list, with what indication, and with what conditions or restrictions.

The meeting is webcast live; an archive recording and transcript are published in the docket within several weeks. The committee's vote is advisory — the final decision is made by the FDA Commissioner — but PCAC recommendations are typically followed.

How to Watch

The Federal Register notice will include a link to the live webcast and a phone-in number for listeners. No registration is required to listen; only registration is required to speak. Most regulators, attorneys, and trade-press journalists watch via the webcast.

Realistic Outcomes After the Vote

Three primary outcomes are possible per peptide.

Recommended for inclusion with the nominated indication. The committee endorses adding the peptide with the indication on file. This is the most favorable outcome from the research-community perspective. If the FDA Commissioner accepts the recommendation, compounding pharmacies will be able to legally make the peptide for individual patient prescriptions tied to the nominated indication. Off-label prescribing for other uses remains at physician discretion.

Recommended for inclusion with conditions. The committee endorses inclusion but requests specific conditions — purity standards, prescribing guardrails, post-market surveillance requirements, restricted patient populations. Conditions can be substantive enough to limit access (for example, restricting prescribing to specialists in a defined disease) or relatively minimal (purity testing requirements that compounders can meet).

Not recommended for inclusion. The committee declines to add the peptide. Reasons typically include insufficient safety data, insufficient efficacy data for the nominated indication, or a determination that the existing alternatives (FDA-approved finished drugs) cover the indication adequately. Non-recommendation does not bar future review, but the timeline for re-nomination is typically multi-year.

Historically, PCAC has split its votes — some peptides on a multi-substance docket are recommended, others are not. There is no reason to expect this docket to behave differently. Researchers and patients with stake in specific peptides should weight their comment energy toward those substances rather than treating the docket as a single up-or-down vote.

What Happens After the FDA Commissioner Decides

After the PCAC vote, the FDA Commissioner reviews the recommendation and issues a formal decision. The decision is published in the Federal Register and triggers a regulatory update — either an addition to the 503A bulks list or a formal denial. Compounding pharmacies update their formularies based on the published list. Physicians wishing to prescribe a newly-included peptide can do so once their preferred compounding pharmacy stocks the substance.

Where to Get Research-Quality Peptides Today

Until and unless the PCAC vote results in 503A inclusion, the legal pathway for these peptides remains the research-chemical channel. Researchers sourcing compounds for laboratory or animal study should select vendors with documented purity testing, transparent sourcing, and a track record of accurate certificates of analysis. WolveStack receives a small commission on referred purchases, which funds our research and writing — this does not affect our editorial evaluation of any vendor.

Common Mistakes in First-Time FDA Comments

• Submitting at the last minute. Regulations.gov experiences traffic spikes near major deadlines. Submit at least 24 hours before the cutoff to avoid technical issues.
• Citing community sources as evidence. Reddit threads, podcast interviews, and biohacker blog posts are not weighted by the committee even if the underlying claim is accurate. Cite the peer-reviewed source instead.
• Confusing 503A and 503B. The current docket is about 503A (individual-patient compounding). 503B is a separate pathway for outsourcing facilities that produce larger batches. Comments should reference 503A specifically; mixing them undermines credibility.
• Arguing against FDA jurisdiction. Comments that question whether the FDA should regulate compounding at all are typically discarded as off-topic. The committee's authority is established; comments that engage with the substantive questions are far more effective.
• Asking for outcomes the committee cannot deliver. The PCAC cannot approve a peptide as a finished drug, change the controlled-substance schedule, or override existing FDA regulations. It can only vote on 503A bulks list inclusion. Comments that ask for outcomes outside the committee's scope are usually ignored.
• Forgetting to upload supporting documents. If you cite a study, the regulations.gov form has an upload field where you can attach the PDF. Uploaded documents become part of the record and are accessible to committee members.
• Submitting once and forgetting. You can submit multiple comments. If you have additional evidence after July 9, submit a follow-up comment before July 22. Each submission is logged independently.

Why This Docket Is the Highest-Leverage Civic Action Available

Public comment dockets are one of the few corners of federal regulatory practice where individual input demonstrably moves the outcome. PCAC committee members read the comments. The published meeting transcripts cite specific public submissions. The vote tallies are influenced by the volume and substance of input.

For peptide-using researchers, clinicians, and patients, the asymmetry is striking: thirty minutes of writing a careful comment can carry as much weight as years of community advocacy that never reached the regulatory record. The cost is trivial; the leverage is real.

For peptide-skeptical readers, the same channel is open. The committee values dissent — comments that flag safety concerns, methodological weaknesses in the evidence base, or specific patient harms add critical balance to the record and are weighted accordingly.

The docket closes July 22. The pre-read cutoff is July 9. The decision shapes the legal landscape for at least the next several years. There is no benefit to waiting.

Frequently Asked Questions